Drugs online research references
Ther Hung. 1980;28(1):17-20.
Observations with a combined oral contraceptive (Rigevidon) containing minimum oestrogen dose.
Karsay K.
PIP: The effects of Rigevidon, a new low-hormone d-norgestrel variant of oral contraceptive, and of Bisecurin, a widely used oral contraceptive, were examined during a period of 3 cycles in 100 women. Gynecological and laboratory examinations were performed. Total number of cycles for Rigevidon (n=50) was 141; for Bisecurin (n=50), 147. Minimal duration of tablet consumption was 2 days for the Rigevidon group and 9 days for the Bisecurin group. 3 women discontinued the Rigevidon treatment for reasons of ocular pain, increased bleeding, and fear of overweight. Bisecurin was discontinued in 1 woman because of hypermenorrhea. The patients were aged 17-44; mean age for the Rigevidon group was 27.3, for the Bisecurin group, 27.8. Majority of the women were multiparas. The incidence of unwanted side effects was almost identical in the 2 groups. Inspite of Rigevidon's low doses, breakthrough bleeding did not occur more frequently than expected. Breast distension occurred more frequently in the Bisecurin group while weight gain occurred more often in the Rigevidon group. The results were highly influenced by the intelligence level of the examined persons. The 2 pregnancies which occurred (1 in each group) should be related to this fact as regular tablet intake was questionable in these cases. Overall, extended use of Rigevidon may be recommended. Its safety and effectiveness are comparable with that of Bisecurin. Its great advantage is its low hormone content. It may be recommended especially for new pill users if the consequences caused by higher estrogen doses are to be avoided.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7281074&dopt=Abstract
word match triphasil online literature
Nahrung. 1981;25(8):779-88.
[Effect of contraceptives on the digestibility of dietary protein and nitrogen balance]
[Article in German]
Gruhn K, Hennig A, Klinger G, Krause G.
The present paper deals with the effects of the hormonal contraceptives Deposiston and Gravistat on the digestibility of dietary crude protein and on the urine excretion of nitrogen. The substances under test were given to nine women aged between 18 and 25 years. The faecal and the urinary nitrogen were determined in the first two cycles during which no contraceptives were used, and also in the subsequent three cycles during which Deposiston and Gravistat were taken by mouth. The preperiod extended over 3 days; and the sampling period, over 4 days. The apparent digestibility of the dietary protein was but slightly increased by the contraceptives. In case of Deposiston for example, it amounted to 85.0% (1st cycle), 86.0% (2nd cycle), 87.3% (3rd cycle), 87.1% (4th cycle), and 88.2% (5th cycle). Deposiston and Gravistat did not affect the urine excretion of nitrogen and the nitrogen balance.
PIP: The present paper deals with the effects of the hormonal contraceptives Deposiston and Gravistat on the digestibility of dietary crude protein and on the urine excretion of nitrogen. The substances under test were given to 9 women between 18-25 years of age. The fecal and urinary nitrogen were determined in the first 2 cycles during which no contraceptives were used, and also in the subsequent 3 cycles during which Deposiston and Gravistat were taken by mouth. The preperiod extended over 3 days and the sampling for 4 days. The apparent digestibility of the dietary protein was only slightly increased by the contraceptives. In the case of Deposiston, it amounted to 85.0% (1st cycle), 86.0% (2nd cycle), 87.3% (3rd cycle), 87.1% (4th cycle), and 88.2% (5th cycle). Deposiston and Gravistat did not affect the urine excretion of nitrogen nor the nitrogen balance. (author's)
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7290175&dopt=Abstract
word match triphasil online literature
Contracept Technol Update. 1986 September;7(9):101-4.
On 7/7/7 preferred for new patients by 47% of respondents.
[No authors listed]
PIP: According to the "Contraceptive Technology Update" (CTU) Spring 1986 Oral Contraceptive (OC) Survey, more than half of 609 respondents reported that they would prescribe a triphasic OC as their 1st choice for a new OC user. A majority of the remaining respondents selected OCs with 30-35 micrograms of estrogen. No respondent selected a high-dose OC as 1st or 2nd choice. When asked about specific OC preferences, CTU readers, ranked the following OCs as their top choices: ON 7/7/7, made by Orthopharmaceuticals, preferred by nearly half of the respondents; Ortho Novum 1/35, also made by Ortho, selected by almost 1/4 of the respondents; Triphasil, produced by Wyeth Laboratories, chosen by 5.4% of respondents; and Norinyl 1+35, a Syntex Laboratories product, preferred by 4.4% of the respondents. The strong preference for ON 7/7/7 was due to 6 major trends, according to Dr. Robert A. Hatcher: heavy marketing; the pharmaceutical company's desire to promote a new product when the patent rights on its standard OC, 1/35, have expired; physician interest in using a slightly lower progestin OC (-25%) without increased spotting; low prices to a number of public family planning programs; state or national purchasing patterns that may limit individual clinicians' OC choices; and clinicians' desires to lower 25% the amount of norethindrone in a 1/35 pill. When asked to name a 2nd choice OC, clinicians again stated a clear preference for low-dose and triphasic OCs. Ortho Novum 1/35 was the OC most often named as a 2nd choice (30%). According to Dr. David A. Grimes, professor of obstetrics and gynecology at the University of Southern California School of Medicine, the trend to prescribe low-dose OCs mirrors a national movement. Grimes reported that the 1985 National Disease and Therapeutic Index showed that nearly 2/3 of women beginning an OC regimen for the 1st time were prescribed 30-35 microgram OCs. He stated that "studies show there are increased risks of vascular disease with 50-microgram pills." Although survey respondents showed a marked preference for triphasics and those who spoke with CTU cited lower total estrogen dosage as 1 reason for their preference, few data exist comparing triphasics and fixed-dose OCs. Grimes states that the limited data available on triphasics and fixed low-dose preparations "suggest that the two are comparable in both incidence of side effects and in efficacy," and that the primary advantage to triphasics is theoretical, i.e., contraceptive efficacy is being maintained while lowering further the total hormone dose.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12268337&dopt=Abstract
word match triphasil online literature
Herbs and Pharmaceuticals Online ||
Hair Million herbal formula for hair loss and hair growth ||
Antibiotics and prescription medications online literature ||